scholarly journals CN-09 * POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME AND PRIMARY BRAIN TUMORS

2014 ◽  
Vol 16 (suppl 5) ◽  
pp. v47-v48
Author(s):  
C. Kamiya-Matsuoka ◽  
D. Cachia ◽  
T. Armstrong ◽  
M. Gilbert
Keyword(s):  
Brain Tumors ◽  
Posterior Reversible Encephalopathy Syndrome ◽  
Posterior Reversible Encephalopathy ◽  
Primary Brain Tumors ◽  
Reversible Encephalopathy

scholarly journals Primary brain tumors and posterior reversible encephalopathy syndrome

2014 ◽  
Vol 1 (4) ◽  
pp. 184-190 ◽  
Author(s):  
Carlos Kamiya-Matsuoka ◽  
David Cachia ◽  
Adriana Olar ◽  
Terri S. Armstrong ◽  
Mark R. Gilbert
Keyword(s):  
Brain Tumors ◽  
Posterior Reversible Encephalopathy Syndrome ◽  
Vasogenic Edema ◽  
Diffuse Intrinsic Pontine Glioma ◽  
Chemotherapeutic Agents ◽  
Cancer Center ◽  
Female Ratio ◽  
Posterior Reversible Encephalopathy ◽  
Primary Brain Tumors ◽  
Reversible Encephalopathy

Abstract Background Posterior reversible encephalopathy syndrome (PRES) is a neurotoxic encephalopathic state associated with reversible cerebral vasogenic edema. It is an increasingly recognized occurrence in the oncology population. However, it is very uncommon in patients with primary brain tumors (PBTs). The aim of this study was to analyze the clinicoradiological features and report the clinical outcomes of PRES in PBT patients. Methods We identified 4 cases with PBT who developed PRES at MD Anderson Cancer Center (MDACC) between 2012 and 2014. Clinical and radiological data were abstracted from their records. In addition, we also solicited 8 cases from the literature. Results The median age at PRES onset was 19 years, male-to-female ratio was 1:1, and the syndrome occurred in patients with ependymoma (n = 4), glioblastoma (n = 3), diffuse intrinsic pontine glioma (DIPG; n = 3), juvenile pilocytic astrocytoma (n = 1), and atypical meningioma (n = 1). Two glioblastomas and 2 DIPG cases received bevacizumab and vandetanib before the onset of symptoms, respectively. The most common clinical presentation was seizures (n = 7). Three MDACC patients recovered completely in 3–4 weeks after the onset of symptoms. One patient died due to active cancer and several comorbidities including PRES. Conclusions Hypertension seems to be the most important coexisting risk factor for development of PRES; however, the potential effects of chemotherapeutic agents in the pathogenesis of PRES should also be examined. The clinicoradiological course of PRES in PBT patients did not vary from the classical descriptions of PRES found in other causes. PRES must be considered as part of the differential diagnosis in patients with PBTs presenting with seizures or acute encephalopathy.

Posterior Reversible Encephalopathy Syndrome

2011 ◽  
Vol 3 (9) ◽  
pp. 424-425
Author(s):  
Dr. Safiya I Shaikh ◽  
◽  
Dr. C Govindaraju Dr. C Govindaraju
Keyword(s):  
Posterior Reversible Encephalopathy Syndrome ◽  
Posterior Reversible Encephalopathy ◽  
Reversible Encephalopathy

Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue

2015 ◽  
Vol 10 (2) ◽  
pp. 180-183 ◽  
Author(s):  
Wala Kridis ◽  
Moez Mdhaffer ◽  
Yosr Hentati ◽  
Fatma Kammoun ◽  
Abir Milad ◽  
...  
Keyword(s):  
Posterior Reversible Encephalopathy Syndrome ◽  
Posterior Reversible Encephalopathy ◽  
Sensitive Issue ◽  
Reversible Encephalopathy

Posterior reversible encephalopathy syndrome as the first clinical manifestation of lupus nephritis

2021 ◽  
Author(s):  
Frederico Carvalho de Medeiros ◽  
Bárbara Márcia Rocha Sousa ◽  
Dandara Noária Cruz Santos ◽  
Gisele Novais Matias Sion ◽  
Cibele Fontes Alves
Keyword(s):  
Lupus Nephritis ◽  
Clinical Manifestation ◽  
Posterior Reversible Encephalopathy Syndrome ◽  
Posterior Reversible Encephalopathy ◽  
Reversible Encephalopathy
Sign in / Sign up

Export Citation Format

Share Document